TEL AVIV, Israel, April 26, 2017 /PRNewswire/ — 2breathe Technologies Ltd. with its wholly owned U.S. subsidiary Resperate Inc. announced, today, the publication of a new peer reviewed original article with the results from a 96 heart failure patients study.
The independent study used the company’s FDA-cleared hypertension treatment wwwice, RESPeRATE. The study demonstrated that using RESPerATE during 12-weeks in the home setting can improve exercise capacity, left ventricular function, accompanied by a reduction in end-diastolic diameter of the left ventricle and attenuation of sleep disturbances, mainly central apnea.
About RESPeRATE & 2breathe
RESPeRATE is the only non-drug, FDA-Cleared wwwice for lowering blood pressure naturally. It is clinically proven, doctor recommended and has no side effects.
2breathe is a smart wwwice and mobile App that guides your breathing to induce sleep. 2breathe uses the RESPeRATE technology to calm you down through slow breathing with prolonged exhalation, which works on the pre-sleep tension, relaxes your sympathetic brain activity and helps you sleep faster and longer